 Lymphoma, Large B-Cell, Diffuse
"Lymphoma, Large B-Cell, Diffuse" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
| Descriptor ID |
D016403
|
| MeSH Number(s) |
C04.557.386.480.150.585 C15.604.515.569.480.150.585 C20.683.515.761.480.150.585
|
| Concept/Terms |
Lymphoma, Large B-Cell, Diffuse- Lymphoma, Large B-Cell, Diffuse
- Diffuse Large-Cell Lymphoma
- Diffuse Large Cell Lymphoma
- Diffuse Large-Cell Lymphomas
- Large-Cell Lymphomas, Diffuse
- Lymphomas, Diffuse Large-Cell
- Diffuse, Large B-Cell, Lymphoma
- Histiocytic Lymphoma
- Histiocytic Lymphomas
- Lymphomas, Histiocytic
- Histiocytic Lymphoma, Diffuse
- Diffuse Histiocytic Lymphoma
- Diffuse Histiocytic Lymphomas
- Histiocytic Lymphomas, Diffuse
- Lymphoma, Diffuse Histiocytic
- Lymphomas, Diffuse Histiocytic
- Large Lymphoid Lymphoma, Diffuse
- Lymphoma, Large-Cell
- Large-Cell Lymphomas
- Lymphoma, Large Cell
- Lymphomas, Large-Cell
- Large-Cell Lymphoma, Diffuse
- Large Cell Lymphoma, Diffuse
- Lymphoma, Diffuse Large-Cell
- Lymphoma, Diffuse Large Cell
- Lymphoma, Histiocytic
- Lymphoma, Histiocytic, Diffuse
- Lymphoma, Large Cell, Diffuse
- Lymphoma, Large Lymphoid, Diffuse
- Lymphoma, Large-Cell, Diffuse
- Large-Cell Lymphoma
- Large Cell Lymphoma
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, Large B-Cell, Diffuse".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, B-Cell [C04.557.386.480.150]
- Lymphoma, Large B-Cell, Diffuse [C04.557.386.480.150.585]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, B-Cell [C15.604.515.569.480.150]
- Lymphoma, Large B-Cell, Diffuse [C15.604.515.569.480.150.585]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, B-Cell [C20.683.515.761.480.150]
- Lymphoma, Large B-Cell, Diffuse [C20.683.515.761.480.150.585]
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, Large B-Cell, Diffuse".
This graph shows the total number of publications written about "Lymphoma, Large B-Cell, Diffuse" by people in this website by year, and whether "Lymphoma, Large B-Cell, Diffuse" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 2 | 0 | 2 | | 1981 | 1 | 0 | 1 | | 1982 | 1 | 0 | 1 | | 1985 | 1 | 0 | 1 | | 1987 | 1 | 0 | 1 | | 1989 | 1 | 0 | 1 | | 1991 | 3 | 0 | 3 | | 1996 | 3 | 0 | 3 | | 1997 | 0 | 1 | 1 | | 1998 | 3 | 0 | 3 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 3 | 1 | 4 | | 2002 | 1 | 0 | 1 | | 2003 | 2 | 0 | 2 | | 2004 | 0 | 1 | 1 | | 2006 | 0 | 1 | 1 | | 2007 | 2 | 0 | 2 | | 2008 | 3 | 1 | 4 | | 2009 | 4 | 2 | 6 | | 2010 | 0 | 1 | 1 | | 2011 | 3 | 2 | 5 | | 2012 | 4 | 0 | 4 | | 2013 | 2 | 0 | 2 | | 2014 | 3 | 0 | 3 | | 2015 | 3 | 0 | 3 | | 2016 | 7 | 1 | 8 | | 2017 | 4 | 0 | 4 | | 2018 | 1 | 0 | 1 | | 2019 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Lymphoma, Large B-Cell, Diffuse" by people in Profiles.
-
Guadamuz JS, Ozenberger K, Qato DM, Ko NY, Saffore CD, Adimadhyam S, Cha AS, Moran KM, Sweiss K, Patel PR, Chiu BC, Calip GS. Mediation analyses of socioeconomic factors determining racial differences in the treatment of diffuse large B-cell lymphoma in a cohort of older adults. Medicine (Baltimore). 2019 Nov; 98(46):e17960.
-
Parker K, Venkataraman G. Challenges in the Diagnosis of Gray Zone Lymphomas. Surg Pathol Clin. 2019 Sep; 12(3):709-718.
-
Godfrey J, Tumuluru S, Bao R, Leukam M, Venkataraman G, Phillip J, Fitzpatrick C, McElherne J, MacNabb BW, Orlowski R, Smith SM, Kline J. PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype. Blood. 2019 05 23; 133(21):2279-2290.
-
Wang YL. MYD88 Mutations and Sensitivity to Ibrutinib Therapy. J Mol Diagn. 2018 03; 20(2):264-266.
-
Riedell PA, Smith SM. Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL? Clin Lymphoma Myeloma Leuk. 2018 02; 18(2):91-97.
-
Kunder C, Cascio MJ, Bakke A, Venkataraman G, O'Malley DP, Ohgami RS. Predominance of CD4+ T Cells in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma and Identification of a Subset of Patients With Peripheral B-Cell Lymphopenia. Am J Clin Pathol. 2017 Jun 01; 147(6):596-603.
-
Galanina N, Smith SM, Liao C, Petrich A, Libao B, Gartenhaus R, Westin JR, Cohen KS, Knost JA, Stadler WM, Doyle A, Karrison T, Gordon LI, Evens AM. University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. Br J Haematol. 2018 04; 181(2):264-267.
-
Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, Segal J, Li S, Zhou S, Santos D, Richard S, Sharma S, Chen W, Oriabure O, Liu Y, Huang S, Guo H, Chen Z, Tao W, Li C, Wang J, Fang B, Wang J, Li L, Badillo M, Ahmed M, Thirumurthi S, Huang SY, Shao Y, Lam L, Yi Q, Wang YL, Wang M. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clin Cancer Res. 2017 Aug 01; 23(15):4212-4223.
-
Xiao DY, Luo S, O'Brian K, Ganti A, Riedell P, Sanfilippo KM, Lynch RC, Liu W, Carson KR. Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy. Am J Hematol. 2016 10; 91(10):1002-7.
-
Galanina N, Jasielec J, Peace D, Smith SM, Nabhan C. Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2017 03; 58(3):752-753.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|